EXPRESS MAIL MAILING LABEL NO. EV 928084169 US

PATENT
Attorney Docket No. INL-091

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Cauwenberghs *et al.*		
SERIAL NO.:	10/019,740	GROUP NO.:	1641
FILING DATE:	December 28, 2001	EXAMINER:	Jung, Unsu
TITLE:	*Detection of von-Willebrand Factor (vWF) Activity*		

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF DR. HANS DECKMYN UNDER 37 C.F.R. § 1.132

Dear Sir:

I, Dr. Hans Deckmyn, hereby declare and state as follows:

1. I am a recognized expert in the field of von Willebrand's disease and have been working in this field for many years. My *curriculum vitae*, which includes my educational and employment history and a list of my publications and patents, is attached hereto as Exhibit A. My present position is Professor of Chemistry at KU Leuven Campus Kortrijk. I am also a board member of the Belgian Society on Thrombosis and Haemostasis and an executive officer of the European Thrombosis Research Organization.

2. I am a co-inventor of the subject matter claimed in the patent application U.S. Serial No. 10/019,740 ("the present application"). I understand that the present application has an effective filing date of July 5, 1999.

3. I have been asked to evaluate the following:

   Whether the collagen-binding assay (CBA) and the ristocetin cofactor assay were art-recognized equivalents at the time of the invention in methods for measuring von Willebrand factor (vWF) activity and whether employing the CBA or the ristocetin

cofactor assay in a diagnostic method would materially affect the diagnosis of von Willebrand's disease?

My analysis in light of the state of the art at the time the present application was filed (1999) follows.

4. von Willebrand's disease is the most-common inherited bleeding disorder caused by defects or deficiencies in vWF. vWF is an adhesive plasma protein essential to hemostasis. vWF possesses multiple functions and activities. For example, during hemostasis and coagulation, vWF permits adhesion of platelets to sites of vascular damage. vWF also binds to tissue matrix proteins including collagen. In plasma, vWF exists in a multimeric dimer configuration, ranging in size from small multimers to large multimers. The larger the vWF molecule, the greater its adhesive capacity.

5. von Willebrand's disease is a heterogeneous disorder. Sometimes, it is caused by the absence of the larger multimers also known as high molecular weight (HMW) vWF multimers. Sometimes, it is caused by the reduction or absence of all forms of vWF multimers. On other occasions, it is caused by mutations on the vWF protein that affect its specific functions. Depending on the nature of the defects or deficiencies, von Willebrand's disease can be classified into three major categories, namely, types 1, 2 and 3. Type 2 von Willebrand's disease can be further divided into subtypes 2A, 2B, 2M and 2N. Subtype 2A is associated with decreased vWF-dependent platelet function due to absence of HMW vWF multimers. Subtype 2B is associated with increased affinity of vWF for platelet glycoprotein 1b (GP1b) and typically is also associated with loss of HMW vWF multimers. Subtype 2M is associated with decreased vWF-dependent platelet function not due to loss of HMW vWF multimers. Subtype 2N is associated with decreased affinity of vWF for factor VIII but has normal vWF-dependent platelet function.

6. The precise diagnosis of types and subtypes of a patient's von Willebrand's disease is crucial in assessing the hemorrhagic risk and determining optimal therapeutic treatment for the patient. The precise diagnosis of von Willebrand's disease, in turn, requires comprehensive laboratory and/or clinical testing. Because of the heterogeneous nature of von Willebrand's disease, no single assay is robust enough to permit detection of all von

Willebrand's disease types and subtypes in a patient. Due to limitations of each assay, a test panel is therefore required to pinpoint specific defects entailed on vWF.

7. At the time the present application was filed (1999), a number of diagnostic assays were known which detect different properties of vWF, among which were the CBA and the ristocetin cofactor assay. The following paragraphs describe the state of art in 1999 with respect to the CBA and the ristocetin cofactor assay.

a. The CBA method measures the ability of vWF to bind to collagen, *i.e.*, the collagen-binding activity. The ristocetin cofactor assay, on the other hand, measures a specific vWF activity, *i.e.*, the ability of vWF to bind to the GP1b complex present on the surface of platelets in the presence of ristocetin or botrocetin (*i.e.*, the platelet GP1b-binding activity), which reflects the platelet adhesion and/or aggregation function of vWF in plasma. Therefore, the CBA and the ristocetin cofactor assay measures clearly distinct vWF activities associated with distinct biochemical functions.

b. At the molecular level, it was known in 1999 that the collagen-binding activity of vWF primarily involves the functional domain A3 of mature vWF. The platelet GP1b-binding activity of vWF primarily involves the functional domain A1. Mutations in functional domain A1 were known to be associated with a number of variants in subtypes 2A, 2B and 2M of von Willebrand's disease, while no mutations in functional domain A3 were known to be associated with any subtypes of von Willebrand's disease in 1999.

c. Procedurally, the CBA method uses ELISA test to measure the collagen-binding activity of vWF using immobilized collagen. The assay was developed based on collagen's selective ability to primarily recognize HMW vWF multimers. The CBA method, however, detects only some 30% of total vWF present in plasma. As a result, the CBA method provides very good information on the HMW multimers of vWF present, but does not provide a good estimate of total level of vWF. The ristocetin cofactor assay, on the other hand, uses ristocetin-induced platelet aggregation or agglutination procedure to measure the platelet GP1b-binding activity of vWF. The ristocetin cofactor assay provides an estimate of the total level of vWF present and additional information on the quality of vWF present related to the size of multimers and specific functional defects. Thus, whereas both the CBA

method and the ristocetin cofactor assay are capable of detecting patients with subtypes 2A and 2B von Willebrand's disease due to the absence of HMW vWF multimers in the patients' plasma, only the ristocetin cofactor assay is sensitive in detecting patients with subtype 2M due to functionally defective vWF unrelated to a loss of HMW vWF forms.

8. Accordingly, the CBA and the ristocetin cofactor assay were not art-recognized equivalents at the time of the invention for measuring vWF activity. Employing the CBA or the ristocetin cofactor assay materially affects the diagnosis of von Willebrand's disease.

9. I further declare that all statements made in this Declaration are of my own knowledge, are true, and that all statements made on information and belief are believed to be true. Moreover, these statements were made with the knowledge that willful false statements and the like made by me are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: 15 February 2007 By: Hans Deckmyn

Dr. Hans Deckmyn

Express Mail Mailing No. EV 928084169 US

Exhibit A

Curriculum Vitae Hans DECKMYN

Born: February 5, 1953 - Roeselare, Belgium
Married to Liesbeth Lybeer
Children: Ilse (1980), Sam (1982), Thomas (1984)
Home address: Lemingstraat 1, B-3210 Linden (Belgium)
tel: 32 16 256694

Office address: Laboratory for Thrombosis Research
Interdisciplinary Research Center
KU Leuven, Campus Kortrijk
E. Sabbelaan 53 B-8500 Kortrijk (Belgium)
tel.: 32-56.246.171 (office), .422 (lab)
fax: 32-56.246.997
e-mail: Hans.Deckmyn@kuleuven-kortrijk.be

Education

High-School: Latin-Science, Klein Seminarie, Roeselare

University: 1974: Bacchelor in Chemistry, KU Leuven, Campus Kortrijk
1976: Biochemist, KU Leuven
1980: Ph.D. Biochemistry, KU Leuven

Military service: 1980 (february-november)

Professional positions

1977: Part-time assistant, KU Leuven

1977-1980: Doctoral student Laboratory for Biochemistry (Prof. G.Préaux)

1981-1985: Postdoc Center for Thrombosis and Vascular Research, (Prof. M. Verstraete, Prof. J. Vermylen)

1985-1987: Postdoc Division of Hematology-Oncology, Washington University School of Medicine, St.Louis Mo, USA (Prof. P.W. Majerus),

1988-1992: Senior Researcher (eerstaanwezend assistent) Center for Molecular and Vascular Biology KU KU Leuven (Prof. D. Collen, Prof. J. Vermylen)

1992-1996: Associate Professor in Chemistry (hoofddocent) KU Leuven Campus Kortrijk

1994-present: Head of the Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk

1996-1999: Professor in Chemistry (hoogleraar) KU Leuven Campus Kortrijk

1999-present: Full Professor in Chemistry (gewoon hoogleraar) KU Leuven Campus Kortrijk

other

2000-2006: Chairman Interdisciplinary Research Center (IRC), KU Leuven Campus Kortrijk
2004-present Spokesman "Interfacultary Center for Biomacromolecular Structure Research" (BioMacS) KU Leuven http://biomacs.kuleuven.be/index.htm
2002-present Board member 'Belgian Society on Trombosis and Haemostasis' (BSTH)
2007-present Executive Officer 'European Thrombosis Research Organisation' (ETRO)
2005-present Board member 'European Cardiovascular Genetics Institute' (ECGI)

Awards

1978-1979:	Post-graduate fellowship I.W.O.N.L. (Institute for the Advancement of Scientific Research in Industry and Agriculture, Belgium)
1985:	Prize Boehringer-Ingelheim for Research on Thrombosis and Coagulation
1985-1987:	NATO Research Fellowship
1985-1986:	Fulbright Research Award
1989:	Young Investigator Award XIIth Congress on Thrombosis and Hemostasis
1991:	European Thrombosis Research Organisation (ETRO) Travel grant
1991:	Prize "Dr. en Mevr. Schamelhout-Koettlitz "-Foundation for Scientific Research (Royal Academy of Medicine of Belgium)
1992	Fellowship "Belgian Action against Cancer"
1993	Triannual Prize Baron Simonart Foundation for Clinical Pharmalogical Research
1995	Awardee Research grant O.Dupont Foundation (Royal Academy of Medicine of Belgium)
1997	Visiting professor "Pro Renovanda" University of Debrecen, Hongarije, Medical School
2004:	Triannual price *Sidmar* for 'Medical Scientific Research' Royal Academy for Medicine of Belgium

Memberships, meetings, journals

1. *International Society on Thrombosis and Haemostasis* (ISTH)

1992-present::	Member
1992-8:	Associate Editor Journal of the Society: "Thrombosis and Haemostasis"
1997-8:	Co-chairman of Scientific and Standardisation Committee, Subcommittee on "Platelet Physiology"
1999:	Member Advisory Board " *Thrombosis and Haemostasis*".
1998-present:	Member of the International Advisory Committee for the XVII, XVIII, XIXth Congress of the ISTH, Washington 1999, Parijs 2001, Birmingham 2003, Geneve 2007
2007:	Invited speaker Geneve

2. *Biochemical Society*

1994-present:	member
1994-1998:	Editorial Advisor of "The Biochemical Journal"
1998-2003:	Editor of "The Biochemical Journal"

3. *European Thrombosis Research Organisation* (ETRO)

1995-present:	Laboratory for Thrombosis Research, IRC-KULAK elected member
1997:	Invited speaker ETRO Advanced Teaching Course, Heviz, Hungary
2003:	Invited speaker ETRO Advanced Teaching Course, Blankenberge, Belgium
2007-10:	Executive Officer

4. *Belgian Society on Thrombosis and Haemostasis* (BSTH)
1993-present: member

5. *Vlaamse Leergangen*
1997-present: member

6. *Koninklijke Vlaams Chemische Vereniging*
1998- present: member

Member Scientific Committee European Platelet and Granulocyte Immunobiology Symposium
(Bamberg, Germany 1992, Cambridge, UK 1994, Hammeenlinna, Finland 1996, S'Agaro, Spain, 1998, Amsterdam, 2000)

2007-9 Section Editor: Thrombosis and Haemostasis

Regular reviewer for:
Circulation; Blood; Journal of the American College of Cardiology; Thrombosis and Haemostasis; Thrombosis Research; Biochemical Journal; Arteriosclerosis, Thrombosis and Vascular Biology;

Occasional reviewer for:
European Heart Journal; Fibrinolysis; Journal of Cardiovascular Pharmacology; Hypertension in Pregnancy; Diabetes Research and Clinical Practice; Life Sciences; European Journal of Clinical Investigation; British Journal of Pharmacology; Biochimica et Biophysica Acta; Blood Coagulation & Fibrinolysis; European Journal of Biochemistry

Patent applications

1. "Detection of von-Willebrand factor (vWF) activity"
EP patent Application, Roche Diagnostics 7/1999
Inventors: N. Cauwenberghs, K. Vanhoorelbeke, H. Deckmyn

2. "An anti-GPIb inhibitory monoclonal antibody as an antithrombotic compound"
EP Patent Application, Leuven R&D, 1/2000
Inventors: N. Cauwenberghs, H. Deckmyn

3. "Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial thrombus formation in baboons.
EP provisional patent application, Thromb-X
Inventors : K. Vanhoorelbeke, N. Cauwenberghs, H. Deckmyn

4. "High-throughput platelet function test"
EP provional patent application: ECGF
Inventors: H Deckmyn, I Salles, A Fontayne

Onderwijs/Teaching

1992-present: Introductory course 'General Chemistry': 1st yr students Medicine, Biomedical Sciences, Biochemistry, Biology, Chemistry, Physics, Mathematics (~180/yr)

1992-2003: Chemistry II (Systematics) 1st yr students Biochemistry, Chemistry, Biology

1996-2000: Mechanisms of signal transduction, PhD-training Sciences-Bioengineers-Pharmacy-Biomedical Sciences

1999-present: Cell Biology (part signal Transdcution) : 1st yr students Medicine, Biomedical Sciences (~100/yr)

2005-present: Biochemistry: 1st yr students Biochemistry, Chemistry, Biology,

Publicatielijst/Publication list

I/ Internationale tijdschriften/ International Journals

1. Defreyn G, Deckmyn H, Vermylen J.
A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2.
Thromb. Res. 26, 389-400, 1982

2. Badenhorst PN, Deckmyn H, Vermylen J.
The effect of sulphinpyrazone on whole blood thromboxane and prostacyclin generation in man.
Thromb. Res. 28, 59-66, 1982.

3. Boogaerts MA, Vermylen J, Deckmyn H, Roelant C, Verwilghen RL, Jacobs HS, Moldow CF.
Enkephalins modify granulocyte-endothelial interactions by stimulating prostacyclin production.
Thromb. Haemost.50, 572-575, 1983.

4. Deckmyn H, Proesmans W, Vermylen J.
Prostacyclin production by whole blood from children: impairment in the hemolytic uremic syndrome and excessive formation in chronic renal failure.
Thromb. Res. 30, 13-18, 1983.

5. Spitz B, Deckmyn H, Van Assche FA, Vermylen J.
Prostacyclin production in whole blood throughout normal pregnancy.
Clin.Exp.Hypert.-Hypert. in Pregnancy B2, 191-202, 1983.

6. Vermylen J, Badenhorst PN, Deckmyn H, Arnout J.
Normal mechanisms of platelet function.
Clin. Haematol. 12,107-151, 1983.

7. Vermylen J, Deckmyn H.
Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.
Br.J.Clin.Pharmacol. 15, 17S-22S, 1983.

8. Deckmyn H, Font L, Van Hemelen C, Carreras LO, Defreyn G, Vermylen J.
Low prostacyclin synthetase activity of fetal rat aorta.
Life Sci. 33, 1491-1497, 1983.

9. Deckmyn H, Van Houtte E, Verstraete M, Vermylen J.
Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom.
Biochem. Pharmacol.32, 2757-2762, 1983.

10. Gresele P, Zoja C, Deckmyn H, Arnout J, Vermylen J, Verstraete M.
Dipyridamole inhibits platelet aggregation in whole blood.
Thromb. Haemost. 50, 852-856, 1983.

11. Van Assche FA, Spitz B, Vermylen J, Deckmyn H.
Preliminary observations on treatment of pregnancy induced hypertension with a thromboxane synthetase inhibitor.
Am. J. Obstet. Gynecol. 148, 216-218,1984.

12. Boogaerts MA, Van de Broeck J, Deckmyn H, Roelant C, Vermylen J, Verwilghen RL.
Protective effect of vitamin E on immune triggered granulocyte mediated endothelial injury.
Thromb. Haemost. 51, 89-92, 1984.

13. Deckmyn H, Gresele P, Arnout J, Vermylen J.
BM 13.177 specifically blocks the platelet thromboxane receptor.
Arch. Intern. Pharmacodynam. Ther. 268, 165-166, 1984.

14. Essien EM, Arnout J, Deckmyn H, Vermylen J, Verstraete M.
Blood changes and enhanced thromboxane and 6-keto prostaglandin $F_{1\alpha}$ production in experimental acute plasmodium bergei infection in hamsters.
Thromb. Haemost. 51, 362-365, 1984.

15. Gresele P, Deckmyn H, Arnout J, Vermylen J.
Platelet inhibitory activity of prostacyclin in the presence of erythrocytes as studied with the impedance aggregometer.
Br. J. Haemat. 57, 171-173, 1984.

16. Gresele P, Deckmyn H, Huybrechts E, Vermylen J.
Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D_2.
Biochem. Pharmacol. 33, 2083-2088, 1984.

17. Gresele P, Deckmyn H, Arnout J, Lemmens J, Janssens W, Vermylen J.
BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man.
Lancet i, 991-994, 1984.

18. Deckmyn H, Gresele P, Arnout J, Todisco A, Vermylen J.
Prolonging prostacyclin production by nafazatrom and dipyridamole.
Lancet ii, 410-411, 1984.

19. Spitz B, Deckmyn H, Van Assche FA, Vermylen J.
Prostacyclin in pregnancy.
Eur. J. Obstet. Reprod. Biol. 18, 303-308, 1984.

20. Arnout J, Vanrusselt M, Deckmyn H, Vermylen J, Fiocchi R, Lijnen P, Amery A.
Platelet hypersensitivity to serotonin after prolonged ketanserin intake?
J. Cardiovasc. Pharmacol. 7 (suppl.7), S20-S22, 1985.

21. Ceuppens JL, Vertessen S, Deckmyn H, Vermylen J.
Effects of thromboxane A_2 on lymphocyte proliferation.
Cell. Immunol. 90, 458-463, 1985.

22. De Maeyer P, Deckmyn H, Arnout J, Vermylen J.
Intravenous ionic contrast media cause local prostacyclin release in man
Investigative Radiol. 20, 458-463, 1985.

23. Deckmyn H, Zoja C, Arnout J, Todisco A, D'Hondt J, Vanden Bulcke F, Hendrickx N, Gresele P, Vermylen J.
Partial isolation and function of the prostacyclin regulating plasma factor.
Clin. Sc. 69, 383-393, 1985.

24. Gresele P, Arnout J, Deckmyn H, Vermylen J.
Combining antiplatelet agents: potentiation between aspirin and dipyridamole.
Lancet i, 937-938, 1985.

25. Gresele P, Bounameaux H, Arnout J, Perez-Requejo JL, Deckmyn H, Vermylen J.
Thromboxane A_2 and prostacyclin do not modulate the systemic hemodynamic response to cold in humans.
J. Lab. Clin. Med. 106, 534-541, 1985.

26. Janssens WJ, Deckmyn H, Gresele P, Vermylen J.
BM 13.177 selectively inhibits endoperoxide analog induced vascular contractions.
Arch. Intn'l Pharmacodyn. Ther. 276, 28-34, 1985.

27. Spitz B, Deckmyn H, Van Bree R, Pijnenborg R, Vermylen J, Van Assche FA.
Influence of a vitamin E deficient diet on prostacyclin production by mesometrial triangles and aortic rings from non-diabetic and diabetic rats.
Am. J. Obstet. Gynecol. 151, 116-120, 1985.

28. Van Renterghem Y, Roels L, Lerut T, Gruwez J, Michielsen P, Gresele P, Deckmyn H, Colucci, M, Arnout J, Vermylen J.
Thrombo-embolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney transplants.
Lancet i, 999-1002, 1985.

29. Gresele P, Deckmyn H, Arnout J, Zoja C, Vermylen J.
Lack of synergism between dazoxiben and dipyridamole following administration to man.
Thromb. Res. 37, 231-236, 1985.

30. Vermylen J, Deckmyn H, Arnout J, Gresele P.
A. Schmidt Memorial Lecture: Peroxides in haemostasis and thrombosis.
Haemostasis 15, 8-9, 1985.

31. Vervliet G, Deckmyn H, Carton H, Billiau A.
Influence of prostaglandin E_2 and indomethacin on interferon-gamma production by cultured peripheral blood leukocytes of multiple sclerosis patients and healthy donors.
J. Clin. Immunol. 5, 102-108, 1985.

32. Gresele P, Arnout J, Deckmyn H, Vermylen J.
Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity.
Thromb. Haemost. 55, 12-18, 1986.

33. Vermylen J, Arnout J, Deckmyn H, Xhonneux B, De Clerck F.
Continuous inhibition of the platelet S_2-serotonergic receptors during the long term administration of ketanserin.
Thromb. Res. 42, 721-723, 1986.

34. Vermylen J, Blockmans D, Spitz B, Deckmyn H.
Thrombosis and immune disorders.
Clin. Haematol. 15, 393-412, 1986.

35. Gresele P, Arnout J, Coene MC, Deckmyn H, Vermylen J.
Leukotriene B_4 production by stimulated whole blood: comparative studies with isolated polymorphonuclear cells.
Biochem. Biophys. Res. Commun. 137, 334-342, 1986.

36. Majerus PW, Connolly TM, Deckmyn H, Ross TS, Bross TE, Ishii H, Bansal V, Wilson DB.
The production of phosphoinositide-derived messenger molecules.
Science 234, 1519-1526, 1986.

37. Deckmyn H, Tu SM, Majerus PW.
Guanine nucleotides stimulate soluble phospholipase C in the absence of membranes.
J. Biol. Chem. 261, 16553-16558, 1986.

38. Ceuppens JL, Robaeys G, Verdickt W, Vertessen S, Deckmyn H, Dequeker J.
Immunomodulatory effects of non-steroidal anti-inflammatory agents in vivo on lymphocyte function in vitro.
Arthritis Rheumat. 29, 305-311, 1986.

39. Kienast J, Arnout J, Deckmyn H, Pfliegler G, Hoet B, Vermylen J.
On the role of guanine nucleotide binding regulatory proteins (G-proteins) in signal transduction in human platelets: studies with sodium fluoride (NaF).
Agents Actions, Suppl. 20, 175-180, 1986.

40. Kienast J, Arnout J, Pfliegler G, Deckmyn H, Hoet B, Vermylen J.
Sodium fluoride mimics effects of both agonists and antagonists on intact human platelets by simultaneous modulation of phospholipase C and adenylate cyclase activity.
Blood 69, 859-866, 1987.

41. Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J.
Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
J. Clin. Invest. 80, 1435-1445, 1987.

42. Arnout J, Kienast J, Deckmyn H, Vermylen J.
Prostacyclin stimulatory activity of reducing cofactors in human plasma filtrate. A potential role for uric acid.
Agents and Actions 22, 360-361, 1987.

43. Gresele P, Arnout J, Deckmyn H, Vermylen J.
L-652,343, a novel dual cyclo/lipoxygenase inhibitor, inhibits LTB_4-production by stimulated human polymorphonuclear cells but not by stimulated whole blood.
Biochem. Pharmacol. 36, 3529-3532, 1987.

44. Arnout J, Van Russelt M, Deckmyn H, Vermylen J.
Continuous inhibition of serotonin-induced platelet aggregation during chronic ketanserin administration to man can be detected after plasma pH control.
Haemostasis 17, 344-348, 1987.

45. Gresele P, Blockmans D, Deckmyn H, Vermylen J.
Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and non-responders.
J Pharmacol. Exp. Ther. 246, 301-307, 1988.

46. Falcon C, Pfliegler G, Deckmyn H, Vermylen J.
The platelet insulin receptor: detection, partial characterization, and search for a function.
Biochem. Biophys. Res. Comm. 157, 1190-1196, 1988.

47. Van Geet C, Deckmyn H, Kienast J, Wittevrongel C, Vermylen J.
Dual effect of fluoride on endothelial prostacyclin production: a phospholipase C mediated phenomenon.
Prog. Clin. Biol. Res. 301, 377-381, 1989.

48. Gresele P, Deckmyn H, Arnout J, Nenci GG, Vermylen J.
Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A_2 receptor antagonist in human platelets.
Thromb. Haemost. 61, 479-484, 1989.

49. Hoet B, Falcon C, De Reys S, Arnout J, Deckmyn H, Vermylen J.
R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin.
Blood 75, 646-653, 1990.

50. Van Geet C, Deckmyn H, Kienast J, Wittevrongel C, Vermylen J.
Guanine nucleotide-dependent inhibition of phospholipase C in human endothelial cells.
J. Biol. Chem. 265, 7920-7926, 1990.

51. Deckmyn H, Chew SL, Vermylen J.
Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction.
Thromb. Haemost. 64, 74-79, 1990.

52. Hoet B, Arnout J, Van Geet C, Deckmyn H, Verhaeghe R, Vermylen J.
Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
Thromb. Haemost. 64, 87-90, 1990.

53. Hoet B, Deckmyn H, Arnout J, Vermylen J.
Pharmacological manipulation of the thromboxane pathway in blood platelets.
Blood Coag Fibrinol. 1, 225-234, 1990.

54. Kienast J, Arnout J, Deckmyn H, Van der Schueren B, Vermylen J.
Non-receptor mediated refractoriness in prostacyclin production by human endothelial cells in a continuous flow system is delayed by a low molecular weight plasma fraction devoid of reducing cofactors for peroxide-catalyzed reactions.
Blood Coag. Fibrinol. 1, 609-618, 1990.

55. Stockmans F, Deckmyn H, Gruwez J, Vermylen J, Acland R.
Continuous quantitative monitoring of mural, platelet-dependent, thrombus kinetics in the crushed rat femoral vein.
Thromb. Haemost. 65, 425-431, 1991.

56. Tornai I, Declerck PJ, Smets L, Arnout J, Deckmyn H, Caekebeke-Peerlinck KMJ, Vermylen J.
Measurement of von Willebrand factor antigen in plasma and platelets with an enzyme-linked immunosorbent assay based on two murine monoclonal antibodies.
Haemostasis 21, 125-134, 1991.

57. Gresele P, Deckmyn H, Nenci GG, Vermylen J.
Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders.
TiPS (Trends Pharmacol. Sc.) 12, 158-163, 1991.

58. Stockmans F, Deckmyn H, Vermylen J.
Thrombosis in injured small vessels.
Plast. Reconstr. Surg. 88, 174-175,1991.

59. Deckmyn H, Van Houtte E, Vermylen J.
Disturbed platelet agggregation to collagen associated with an antibody against a 85-90 Kd platelet glycoprotein in a patient with prolonged bleeding time.
Blood 79, 1466-1471, 1992.

60. Vermylen J, Deckmyn H.
Thromboxane synthase inhibitors and receptor antagonists.
Cardiovasc. Drugs Ther. 6,29-33, 1992.

61. Deckmyn H, Van Geet C, Vermylen J.
Dual regulation of phospholipase activity by G-proteins.
News Physiol. Sci. 8,61-63, 1993.

62. Tornai I, Arnout J, Deckmyn H, Peerlinck K, Vermylen J.
A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein Ib - and IIb/IIIa-binding domains.
J. Clin. Invest. 91, 273-282, 1993.

63. De Reys S, Blom C, Lepoudre B, Declerck PJ, De Ley M, Vermylen J, Deckmyn H.
Human platelet aggregation by murine monoclonal antibodies is subtype-dependent.
Blood 81, 1792-1800, 1993.

64. Pfliegler G, Arnout J, Kienast J, Wittevrongel C, Hoet B, Deckmyn H, Vermylen J.
Sodium fluoride induced activation of phospholipase C does not depend on ADP, PAF or arachidonate products.
Thromb. Res. 69, 541-545, 1993.

65. Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J.
MK-383 (L-700,462), a selective non-peptide platelet glycoprotein IIb/IIIa antagonist, is active in man.
Circulation 88, 1512-1517, 1993.

66. Hoet B, Arnout J, Deckmyn H, Vermylen J.
Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Thromb. Haemost. 70, 822-825, 1993.

67. Jaspers M, Vekemans S, Carmeliet G, Van Leuven F, De Strooper B, Deckmyn H, Cassiman JJ.
The α_2-subunit of VLA-2 and the fibrinogen a-chain share an RGD-domain recognized by MAB-3H8.
Hybridoma 12, 467-474, 1993.

68. Kiss RG, Stassen JM, Deckmyn H, Roskams T, Gold HK, Plow EF, Collen D.
Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation.
ArteriosclerThromb 14, 375-380, 1994

69. De Reys S, Hoylaerts MF, De Ley M, Vermylen J, Deckmyn H.
Fc-independent cross-linking of a novel platelet membrane protein by a monoclonal antibody causes platelet activation.
Blood,84, 547-555, 1994

70. Deckmyn H,Stanssens P, Hoet B, Declerck P, Lauwereys M,Gansemans Y, Tornai I, Vermylen J.
An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR_3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function.
Brit J Haematol, 87, 562-571, 1994

71. Matsuno H, Stassen JM, Vermylen J, Deckmyn H
Inhibition of integrin function by a cyclic RGD-containing peptide, prevents neointima formation.
Circulation, 90, 2203-2206, 1994

72. Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Arnout J.
Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein IIb/IIIa receptor antagonist, in healthy men.
Clin Pharm Ther; 56, 377-388, 1994.

73. Deckmyn H, Zhang J, Van Houtte E, Vermylen J.
Production and nucleotide sequence of an inhibitory human IgM autoantibody directed against platelet glycoprotein Ia/IIa.
Blood, 84, 1968-1974, 1994

74. Deckmyn H, De Reys S.
Functional effects of human antiplatelet antibodies.
Seminars Thromb. Haemost.,21, 46-59, 1995.

75. Harsfalvi J, Stassen JM, Van Houtte E, Sawyer RT, Vermylen J, Deckmyn H.
Calin from Hirudo medicinalis: an inhibitor of von Willebrand binding to collagen under static and flow conditions.
Blood, 85, 705-711, 1995

76. Deckmyn H, Stassen JM, Vreys I, Van Houtte E, Sawyer RT, Vermylen J.
Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters
Blood, 85, 712-719, 1995

77. Hoylaerts MF, Nuyts K, Peerlinck K, Deckmyn H, Vermylen J.
Mechanism of ristocetin-induced binding of von Willebrand factor to glycoprotein Ib.
Biochem J, 306, 453-463, 1995

78. Blockmans D, Deckmyn H, Vermylen J
Mechanisms of platelet activation.
Blood reviews, 9, 143-156, 1995

79. Kotzé HF, Badenhorst PN, Lamprecht S, Meiring M, van Wyk V, Nuyts K, Stassen JM, Vermylen J, Deckmyn H
Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal antiplatelet glycoprotein IIb/IIIa antibody in a baboon model..
Thromb. Haemost 74, 751-757, 1995

80. Stassen JM, Lambeir AM, Vreys I, Deckmyn H, Matthyssens G, Nyström A, Vermylen J
Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
Thromb. Haemost. 74, 655-659, 1995

81. Matsuno H, Hoylaerts MF, Vermylen J, Deckmyn H
Inhibition of integrin function prevents restenosis following vascular injury.
Folia Pharmacol Jpn 106, 143-155, 1995

82. Matsuno H, Stassen JM, Vermylen J, Deckmyn H
Fast and reproducible vascular neointima formation in the hamster carotid artery. Effects of trapidil and captopril
Thromb. Haemost. 74, 1591-1596, 1995

83. Blockmans D, Deckmyn H, De Vos R, Vermylen J
Epinephrine induces a late thromboxane-dependent platelet shape change and enhances synergistically the shape change induced by other platelet agonists.
Platelets 7, 35-42, 1996

84. Blockmans D, Deckmyn H, Van den Hove L, Vermylen J
The effect of plasmin on platelet function.
Platelets 7, 139-148, 1996

85. Azerad MA, Harsfalvi J, Deckmyn H, Vermylen J, Michaux JL, Hoylaerts MF
Recirculated normal platelets adhere to surfaces coated with plasma from patients with immune thrombocytopenia.
Blood Coag. Fibrinol. 8, 59-64, 1997

86. Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn H, Vermylen J
von Willebrand factor binds to native collagen VI primarily via its A1 domain.
Biochem.J. 324, 185-191, 1997

87. Depraetere H, Wille C, Gansemans Y, Stanssens P, Lauwereys M, Baruch D, De Reys S, Deckmyn H.
The integrin $\alpha_2\beta_1$ (GPIa/IIa)-I-domain inhibits platelet -collagen interaction.
Thromb. Haemost. 77, 981-985, 1997

88. Deckmyn H, Vanhoorelbeke K, Cauwenberghs N
A platelet activating anti-glycoprotein Ib monoclonal antibody.
Blood 90, 3807-3808, 1997

89. Stockmans F, Deberdt W, Bjerle P, Vermylen J, Nyström Å, Deckmyn H
Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal model
Thromb. Haemost.79, 222-227, 1998

90. Deckmyn H, Vanhoorelbeke K, Peerlinck K
Acquired inhibitory or activating human antiplatelet antibodies.
in ***"Baillière's Clinical Haematology"*** A.Eldor, JJ Michiels Eds 11, 343-359, 1998

91. Ajzenberg N, Depraetere H, Lacombe C, Deckmyn H, Baruch D.
Distinct sequences of the GPIb-binding domain of von Willebrand factor involved in shear-induced platelet aggregation.
Platelets 9, 151-153, 1998

92. Depraetere H, Ajzenberg N, Girma JP, Lacombe C, Meyer D, Deckmyn H, Baruch D
Platelet aggregation induced by a monoclonal antibody to the A1 domain of von Willebrand Factor.
Blood 91, 3792-3799, 1998

93. Deroo S, Fournier P, Theisen D, Brons HC, Deckmyn H, Muller CP
Phage displayed 6-mer mimotopes with a consensus proline absent in the minimized linear wild-type epitope.
Lett. Pept. Sci. 5, 159-162, 1998

94. Depraetere H, Viaene A, Deroo S, Vauterin S, Deckmyn H
Identification of peptides, selected by phage display technology, that inhibit von Willebrand Factor binding to collagen
Blood 92, 4207-4211,1998

95. Depraetere H, Kerekes A, Deckmyn H
The collagen-binding leech products rLAPP and calin prevent both von Willebrand factor and $\alpha 2\beta 1$ (GPIa/IIa)-I-domain binding to collagen in a different manner.
Thromb. Haemost. 82, 1160-1163, 1999

96. Tornai I, Boda Z, Schlammadinger A, Juhasz A, Cauwenberghs N, Deckmyn H,
Harsfalvi J.
Acquired Bernard-Soulier Syndrome: A Case with Necrotizing Vasculitis and Thrombosis.
Haemostasis 29, 229-236, 1999.

97. Vanhoorelbeke K*, Cauwenberghs N*, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H
A new and reproducible vWF-RiCof assay
Thromb. Haemost. 83, 107-113 ,2000 * contributed equally

98. Cauwenberghs N, Meiring M, Lamprecht S, Roodt JP, Vauterin S, Deckmyn H, Kotzé HF
Antithrombotic effect of platelet glycoprotein Ib blocking monoclonal antibody Fab-fragments in a baboon model.
Arterioscl. Thromb. Vasc Biol, 20, 1347-1353, 2000

99. Cauwenberghs N, Ajzenberg N, Vauterin S, Hoylaerts MF, Declerck PJ, Baruch D, Deckmyn H
Characterization of murine anti-GPIb monoclonal antibodies that differentiate between shear-induced and rist/botrocetin-induced GPIb-vWF interaction.
Haemostasis 30 (3), :139-148, 2000

100. Vanhoorelbeke K, van der Plas RM, Vandecasteele G, Vauterin S, Huizinga EG, Sixma JJ, Deckmyn H.
Sequence alignment between vWF and peptides inhibiting the vWF-collagen interaction does not result in the identification of a collagen-binding site in vWF.
Thromb Haemost,84, 621-625, 2000

101. Cauwenberghs N, K. Vanhoorelbeke, S. Vauterin, Deckmyn H.
Structural determinants within glycoprotein Ibalpha involved in its binding to von Willebrand factor
Platelets, 11,373-378, 2000

102. Cauwenberghs N, Schlammadinger A, Vauterin S, Cooper S, Descheemaeker G, Tornai I, Deckmyn H.
Fc-receptor dependent platelet aggregation induced by monoclonal antibodies against platelet glycoprotein Ib or von Willebrand factor.
Thromb Haemost 85: 679–685, 2001

103. Viaene A, A. Crab, M. Meiring, D. Pritchard, H. Deckmyn
Identification of a collagen-binding protein from Necator americanus by using a cDNA-expression phage display library.
J Parasitology,87:619-25, 2001.

104. Ulrichts H, H. Depraetere, J. Harsfalvi, H. Deckmyn
Selection of phages that inhibit von Willebrand Factor interaction with collagen under both static and flow conditions
Thromb Haemost, 86, 630-635, 2001

105. Vanhoorelbeke K, A. Schlammadinger, JP. Delville, J. Handsaeme, G. Vandecasteele, S. Vauterin, O. Pradier, W. Wijns, H. Deckmyn
Occurrence of the Asn45Ser mutation in the GPIX gene in a Belgian patient with Bernard-Soulier syndrome.
Platelets 12: 114-120, 2001

106. Cauwenberghs N, K. Vanhoorelbeke, S. Vauterin, DF. Westra, G. Romo, E. Huizinga, J. Lopez, MC. Berndt, J. Harsfalvi, Deckmyn H.
Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal domains of glycoprotein Ibα
Blood 98:652-660, 2001

107. Monnet E, H. Depraetere, C. Legrand, H. Deckmyn, F. Fauvel-Lafeve
A monoclonal antibody to platelet type III collagen-binding protein (TIIICBP) binds to blood and vascular cells, and inhibits platelet-vessel wall interactions.
Thromb Haemost, 86, 694-635, 2001

108. Hoylaerts MF, Viaene A, Thys C, Deckmyn H, Vermylen J
Anti-vWF antibodies induce GPIbalpha and FcgammaRII mediated platelet aggregation only at low shear stress.
J Thrombosis Thrombolysis, 12, 249-262, 2001

109. Vanhoorelbeke K, Cauwenberghs N, Deckmyn H
A reliable vWF:RiCof ELISA method to differentiate between type I and type II van Willebrand disease.
Seminars in Thrombosis and Hemostasis, 28 (2) Diagnosis and Management of Congenital von Willebrand Disease Guest Editors-JJ. Michiels and AH. Sutor, 2002

110. Wu D., M. Meiring, HF Kotzé, H Deckmyn, N. Cauwenberghs
Inhibition of platelet GPIb, GPIIb/IIIa or both by monoclonal antibodies, prevents arterial thrombus formation in baboons.
Arterioscl. Thromb. Vasc Biol, 22, 323-328, 2002

111. Novak L, Deckmyn H, Damjanovich S, Harsfalvi J
Shear-dependent morphology of von Willebrand Factor bound to immobilized collagen
Blood 99, 2070-2076, 2002

112. D Wu, K Vanhoorelbeke, N Cauwenberghs, M Meiring, H Depraetere, HF. Kotze, H Deckmyn
Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation in baboons
Blood 99, 3623-3628, 2002 * contributed equally
With editorial comment: "Does VWF bind collagen after all?" Evan Sadler
Blood 99, 3491, 2002

113. Crab A, C. Pelicaen, W. Noppe, S. Vauterin, K. Vanhoorelbeke, H. Deckmyn
The parasitic hematophagous worm Haemonchus contortus inhibits human platelet aggregation and adhesion: partial purification of a platelet inhibitor.
Thromb.Haemost.87,899-904, 2002

114. Fatturutto , Deckmyn H., Vanhoorelbeke K., Kotzé H.
A modified Folts model or the Folts model to evaluate new antithrombotics
Blood 101, 782-783, 2003

115. Vanhoorelbeke K., Deckmyn H.
The role of vWF-collagen interaction in acute platelet thrombus formation.
Drugs of the Future, 28, 61-67, 2003

116. Keuren JFW, H. Ulrichts, MAH. Feijge, K.Hamulyàk, H Deckmyn, T Lindhout, JWM. Heemskerk
Involvement of glycoprotein Ib epitopes and integrin alphaIIb beta3 in platelets procoagulant activity of stirred plasma.
J Lab.Clin. Med. 141, 350-358, 2003

117. Vanhoorelbeke K, Ulrichts H, Schoolmeester A, Deckmyn H
Inhibition of platelet adhesion as a new target for antithrombotic drugs.
Current Drug Targets-Cardiovascular & Hematological Disorders 3, 113-128, 2003

118. Vanhoorelbeke K, Depraetere H, Romijn RAP, Huizinga E, De Maeyer M, Deckmyn H
A consensus tetra-peptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the VWF-collagen interaction
J. Biol.Chem 278, 37815–37821, 2003

119. Ulrichts H, Vanhoorelbeke K, Vauterin S, Kroll H, Santoso S, Deckmyn H
The platelet glycoprotein Ibalpha HPA-2 polymorphism affects vWF binding, but not thrombin interaction.
Arterioscl. Thromb. Vasc Biol 23:1302-1307, 2003

120. Vanhoorelbeke K, Ulrichts H, Schoolmeester A, Deckmyn H
Inhibition of platelet adhesion as a new target for antithrombotic drugs.
Current Drug Targets-Cardiovascular & Hematological Disorders 3, 113-128, 2003

121. Vanhoorelbeke K, H Ulrichts, RA Romijn, EG Huizinga, H Deckmyn
The GPIb alpha -thrombin interaction: far from crystal clear
Trends in Molecular Medicine 10: 33-39 , 2004 IF 9.848

122. Siljander PR-M, Munnix ICA, Smethurst PA, Deckmyn H, Rankin A, Lindhout T, Ouwehand WH, Farndale RW, Heemskerk JWM
Platelet receptor interplay regulates collagen-induced thrombus formation in flowing blood
Blood 103, 1333-1341, 2004 IF 10.120
with editorial comment: Platelet collagen receptors play molecular ping-pong .
Mark L. Kahn Blood 103: 1180-1181, 2004.

123. Musaji A, Vanhoorelbeke K, Deckmyn H, Coutelier JP
A New Model of Transient Strain-Dependent Autoimmune Thrombocytopenia in Mice Immunized with Rat Platelets
Experimental Hematology 32: 87-94, 2004 IF 3.4

124. Schoolmeester A, Vanhoorelbeke K, Katsutani S, Depraetere H, Feys H, Heemskerk JMW, Hoylaerts MF, Deckmyn H.
Monoclonal antibody IAC-1 is specific for activated integrin alpha2beta1 and binds to amino acid 199-201 of the integrin alpha2 I-domain,.
Blood 104: 390-396, 2004 IF 10.120
with editorial comment: Dotting the I of an I-domain Joel S Bennett
Blood 104: 299-300, 2004

125. Ulrichts H, K. Vanhoorelbeke, G. Vandewalle, S. Katsutani, S. De Meyer, S. Staelens, H. Deckmyn
New approaches for antithrombotic antiplatelet therapies"
Current Medicinal Chemistry 11, 2261-2273, 2004 IF 4.409

126. JM Stassen, J Arnout, H Deckmyn
The hemostatic system
Current Medicinal Chemistry, 11, 2273-2286, 2004 IF 4.409

127. H. Deckmyn, H. Ulrichts, G. Vandewalle, K. Vanhoorelbeke
Platelet antigens and their function
Vox sanguinis 87 Suppl 2:105-11, 2004 (invited) IF 2.1

128. Ulrichts H., Harsfalvi J., Bene L., Matko J., Vermylen J., Ajzenberg N., Baruch D., Deckmyn H., Tornai I.,
A monoclonal antibody directed against the N-terminal end of human von Willebrand Factor subunit, induces type 2B-like alterations
J. Thromb Haemost 2: 1622–1628, 2004

129. K. Vanhoorelbeke, H. Deckmyn
Inhibitie van von Willebrand Factor binding aan collageen als antitrombotische strategie
Bloedvaten, Hart en Longen 9, 192-195, 2004 (invited)

129bis. K. Vanhoorelbeke, H. Deckmyn
Stratégie antithrombotique via une inhibition de la liaison du fVW au collagène
Vaisseaux, Coeur et Poumons 9, 192-195, 2004

130. M Hellings, Y Engelborghs, H Deckmyn, K Vanhoorelbeke, ME Schiphorst, JW Akkerman, M De Maeyer.
Experimental indication for the existence of multiple Trp rotamers in von Willebrand Factor A3 domain.
Proteins: structure, function and bioinformatics 57, 596-601, 2004

131. Lecut C*, Schoolmeester A*, Broers JLV, van Zandvoort MAMJ, Vanhoorelbeke K, Deckmyn H, Jandrot-Perrus M, Heemskerk JWM
Roles of glycoproteins VI and Ib in integrin activation and thrombus formation on collagen under flow.
Arterioscler Thromb Vasc Biol. 24:1727-1733, 2004. Epub 2004 Jul 01. * contributed equally
IF 6.791

132. W. Noppe, K. Vanhoorelbeke, IY Galaev, B Mattiasson, H Deckmyn Identification and application of lactoferrin-binding phages isolated from phage-displayed peptide libraries.
J Dairy Sci. 87, 3247-3255, 2004 IF 1.9

133. C Lecut, V Arocas, H Ulrichts, A Elbaz, J-L Villeval, J-J Lacapère, H Deckmyn, M Jandrot-Perrus
Identification of residues within human GPVI involved in the binding to collagen: evidence for the existence of distinct binding sites
J. Biol. Chem. 279, 52293-9, 2004 IF 6.482

134. K. Vanhoorelbeke, H. Deckmyn
Inhibitie van von Willebrand Factor binding aan collageen als antitrombotische strategie
Neuron 9, 262-267, 2004

135. K. Vanhoorelbeke, H. Deckmyn
Stratégie antithrombotique via une inhibition de la liaison du facteur von Willebrand au collagène
Neurone 9, 262-267, 2004

136. Vanhoorelbeke K, Pareyn I, Hoylaerts MF, Arnout J, Deckmyn H
Plasma glycocalicin as a source of GPIbalpha in the von Willebrand factor ristocetin cofactor ELISA
Thromb. Haemost. 93, 165-171, 2005 **IF 4.950**

137. Deckmyn H, Cauwenberghs N, Wu D, Depraetere H, Vanhoorelbeke K.
Development of antibodies that interfere with the collagen-vWF-GPIb axis as new antithrombotics
Verhandelingen van de Koninklijke Academie voor Geneeskunde van België 67, 55-65, 2005

138. G. Xu, H. Ulrichts, S. Vauterin, S. De Meyer, H. Deckmyn, M. Teng, L. Niu.
How does agkicetin-C bind on platelet glycoprotein Ibalpha and achieve its platelet effects.
Toxicon 45, 561-570, 2005

139. H. Ulrichts, K. Vanhoorelbeke, S. Vauterin, H. Deckmyn
The functional self-association of von Willebrand Factor is modulated by a multiple domain interaction.
J. Thromb. Haemost. 3, 552-61, 2005.

140. JFW Keuren, SJH Wielders, H Ulrichts, T Hackeng, H Deckmyn, JWM Heemskerk, E Bevers, T Lindhout
Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through PAR-1
Arterioscler Thromb Vasc Biol. 25:1499-505, 2005 **IF** 2005 **7.432**

141. G. Vande Walle, ZS Mayer, E Illyés, J Baert, K Vanhoorelbeke, I Pareyn, H Deckmyn
Two functional active conformations of the integrin alpha2 beta 1, depending on activation condition and cell type.
J Biol Chem 2005;280:36873-82. **IF** 2005 **6.355**

142. DL Hughes, P Stafford, S Hamia, IJ Harmer, A Schoolmeester, H Deckmyn, RW Farndale, WH Ouwehand, NA Watkins
Platelet integrin alpha2 I-domain specific antibodies produced via domain specific DNA vaccination combined with variable gene phage display.
Thromb. Haemost. 94: 1318–26, 2005 **IF** 2005 **3.413**

143. S Staelens, MA Hadders, S Vauterin, C Platteau, M De Maeyer, K Vanhoorelbeke, EG Huizinga, H Deckmyn
Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain
J Biol Chem 2006;281:2225-2231. Epub 2005 Nov 28. **IF** 2005 **6.355**

144. Ulrichts H, Udvardy M, Vanhoorelbeke K, Lenting PJ, Pareyn I, Vandeputte N, Deckmyn H
Shielding of the A1-domain by the amino-terminal domain (AA764-1035) of von Willebrand Factor modulates its interaction with platelet glycoprotein Ib-IX-V.
J. Biol. Chem 2006; 281:4699-707. **IF** 2005 **6.355**

145. De Meyer SF, K Vanhoorelbeke, MK Chuah, I Pareyn, V Gillijns, RP Hebbel, D Collen, H Deckmyn, T VandenDriessche
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor
Blood 2006 107: 4728-4736
with editorial comment by RR Montgomey
A package for VWD endothelial cells
Blood 2006;107 4580-4581

146. Schlammadinger A., Vanhoorelbeke K., Laszlo P, Berecky Z, Muszbek L, Deckmyn H., Boda Z.
Von Willebrand Factor antigen latex immunoassays are affected to a different extent by rheumatoid factor
Clin Appl Thromb Hemost 2006; 12, 242-3

147. Feys HB,Liu F,Dong N,Pareyn I, Vandeputte N, Noppe W, Vauterin S, Ruan C, Deckmyn H, Vanhoorelbeke K
ADAMTS13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences
J Thromb Haemost 2006; 4: 955-962
with commentary by B. Lämmle
A new tool to further explore the role of ADAMTS-13 in health and disease
J Thromb Haemost 2006;4: 952-4

148. Liu F, Feys HB, Dong N, Bai X, Vanhoorelbeke K, Deckmyn H, Ruan C
Determination of the antigen and activity of ADAMTS13 in patients with thrombotic thrombocytopenic purpura and carriers.
Chinese Journal of Hematology - Zhonghua Xue Ye Xue Za Zhi. 2006;27:154-7

149. Noppe W, Plieva FM, Galaev IY, Vanhoorelbeke K, Mattiasson B, Deckmyn H
Phages as affinity ligands for the direct purification of lactorferrin from defatted milk
J Chromatography A 2006; 1101: 79-80

150. Caron C, L Hilbert, K Vanhoorelbeke, H Deckmyn, J Goudemand, C Mazurier
Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ib alpha in an enzyme-linked immunosorbent assay-based : performances in patients with type 2B von Willebrand disease.
Br J Haematol. 2006;133:655-63

151. De Meyer SF, Vanhoorelbeke K, Ulrichts H, Staelens S, Feys HB, Salles I, Fontayne A, Deckmyn H
Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs.
Cardiovasc. Hematol. Disord Drug Targets 2006; 6 (3): 191-207

152. Orr AW , MH Ginsberg, S Shattil, H Deckmyn, MA Schwartz
Matrix-specific suppression of integrin activation in shear stress signalling
Mol Biol Cell 2006;17(11):4686-4697

153. Fontayne A, Vanhoorelbeke K, Pareyn I, Cauwenberghs N, Ngo TH, Dejaeghere D, La Roche Y, Barbeaux P.,Van Rompaey I, Meiring M, Lamprecht S, Roodt J, Stassen JM, Deckmyn H
Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4
Thromb Haemost 2006;96(5):671-84.

154. Deckmyn H, Vanhoorelbeke K
"Inside Blood": When collagen meets VWF
Blood 2006; 108, 3628

155. BA Badlou, G Spierenburg, H Ulrichts, H Deckmyn, WM Smid, JWN Akkerman
Role of Glycoprotein Ibalpha in phagocytosis of platelets by macrophages
Transfusion 2006 Dec;46(12):2090-2099.

156. Pontiggia L, B Steiner, H Ulrichts, H Deckmyn, M Forestier, JH Beer
Platelet microparticle formation and thrombin generation under high shear is effectively suppressed by a monoclonal antibody against GPIb alpha.
Thromb Haemost 2006 Dec;96(6):774-80

157. De Meyer SF, Pareyn I, Baert J, Deckmyn H, Vanhoorelbeke K.
False positive results in chimeraplasty for von Willebrand Disease.
Thromb Res. 2007;119:93-104.

158. Van de Walle GRAJ, A Schoolmeester, BF Iserbyt, JMEM Cosemans, JWM Heemskerk, MF Hoylaerts, A Nurden, K Vanhoorelbeke, H Deckmyn
Activation of αIIbβ3 is a sufficient but also an imperative prerequisite for activation of α2β1 in platelets
Blood 2007;109:595-602

159. K Vanhoorelbeke, H Ulrichts, G Van de Walle, A Fontayne, H Deckmyn
Inhibition of platelet glycoprotein Ib and its antithrombotic potential
Current Pharmaceutical Design in press

160. SM Penz, AJ Reininger, O Toth, H Deckmyn, R Brand, W Siess
Glycoprotein Iba inhibition and ADP receptor antagonists, but not aspirin reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques
Thromb Haemost in press

II. In andere wetenschappelijke tijdschriften/other scientific journals

1. Deckmyn H.
Signaaltransduktie in bloedplaatjes.
Verhandelingen Koninklijke Academie voor Geneeskunde van België 6,575-585, 1991

2. Vauterin S, Viaene A, Deckmyn H
Phage display: een nieuwe selectiemethode
Tijdschrift BVLT, 26, 61-64, 1999

III. Internationale congressen/ Proceedings of congresses

a/Integraal gepubliceerde/ Published in full

1. Vermylen J, Defreyn G, Deckmyn H.
Antiplatelet drugs: a pharmacological survey.
Progr. Pharmacol. 4, 9-19, 1982.

2. Deckmyn H, Gresele P, Arnout J, Vermylen J.
Thromboxane synthase inhibition and thromboxane antagonism.
In: "***Zbornik V. Konference o ateroskerozi in arterijski trombozi.***" Keber D, Stegnar M, Eds., Ljubljana, 61-64, 1986.

3. Deckmyn H, Vermylen J.
Antiplatelet therapy: a review.
In: "***Zbornik V. Konference o ateroskerozi in arterijski trombozi.***" Keber D, Stegnar M, Eds., Ljubljana, 55-60, 1986.

4. Majerus PW, Connolly TM, Ross TS, Ishii H, Deckmyn H.
The role of phosphoinositides in cell physiology.
Anderson Symposium on Fundamental Cancer Research, 39, 157-163, 1987.

VII) Boeken/ Chapters in books

1. Van der Giessen W, Serruys P, Stoel I, Hugenholtz P, De Leeuw P, Van Vliet H, Deckmyn H, Vermylen J.
Acute effect of cigarette smoking on cardiac prostaglandin synthesis and platelet behavior in patients with coronary heart disease.
In: "***Adv. Prost. Thromb. leuk. Res.***, Vol.11", Samuelsson B, Paoletti R, Ramwell P, Eds., Raven Press, New York, 359-364, 1983

2. Deckmyn H, Gresele P, Arnout J, Vermylen J.
Manipulation of pro- and antiaggregating prostaglandins: new antithrombotic strategies.
In: "***Drugs affecting leukotrienes and other eicosanoid pathways.***" Samuelsson B, Berti F, Folco GC, Velo G, Eds., Plenum Publishing Company, London, England, 141-147, 1985.

3. Vermylen J, Deckmyn H, Gresele P, Arnout J.
Antithrombotic potential of thromboxane synthase inhibitors: problems and possible solutions.
In: "***Prostaglandins and other Eicosanoids in the Cardiovascular System.***" Schrör, Ed, Karger, Basel, 445-453, 1985.

4. Gresele P, Arnout J, Deckmyn H, Vermylen J.
Endogenous antiaggregatory prostaglandins can contribute to inhibition of hemostasis: a pharmacological study in vivo in humans.
In: "***Adv. Prost. Thromb. Leuk. Res.***" vol. 17A, Samuelsson B, Paoletti R, Ramwell PW, Eds., Raven Press N.Y., 248-253, 1987.

5. Wilson DB, Connolly TM, Ross TM, Ishii H, Bross TE, Deckmyn H, Brass LF, Majerus PW.
Phosphoinositide metabolism in human platelets.
In: " ***Adv. Prost. Thromb. Leuk. Res.***"." vol. 17A, Samuelsson B, Paoletti R, Ramwell PW, Eds., Raven Press N.Y., 558-562, 1987.

6. Vermylen J, Gresele P, Arnout J, Deckmyn H.
Thromboxane synthase inhibitors: ex vivo studies.
In: "***Biology of Icosanoids.***" Lagarde M, Ed., Colloque INSERM 152, 383-388, 1987.

7. Deckmyn H, Whiteley BJ, Majerus PW.
Phosphatidylinositol phospholipase C.
In: "***G-proteins.***", Birnbaumer L, Iyengar R, Eds., Academic Press, 429-452, 1990.

8. Vermylen J, Deckmyn H.
Antiplatelet agents: pharmacology and clinical use.
In: "***Recent Adv. Blood Coag.***" Poller L, Ed., vol. 6, 125-144, 1993.

9. Badenhorst PN, Kotzé HF, Lamprecht S, Meiring M, van Wyk V, Deckmyn H
Dose-dependent inhibition of acute arterial thrombosis by monoclonal antibody (16N7C2) in a baboon model.
in: "***Radiolabeled Blood Elements.***", ed.: Martin-Comin J,
Plenum Press, NY, pp 343-347, 1994

10. Badenhorst PN, Kotzé HF, Lamprecht S, Meiring M, van Wyk V, Deckmyn H
Dose-dependent inhibition of acute arterial thrombosis by monoclonal antibody (16N7C2) in a baboon model.
in: "***Radiolabeled Blood Elements.***", ed.: Martin-Comin J,
Plenum Press, NY, pp 343-347, 1994

11. Deckmyn H, Vanhoorelbeke K, Peerlinck K
Functional human antiplatelet antibodies.
In: "***Acquired Disorders of Haemostasis: Pathophysiology, Clinical Practice and Basic Research.***" Eldor A, Michiels JJ Eds, "Bailliere's Best Practice and Research in Clinical Haematology" 11, 343-359, 1998

12. Deckmyn H. Vanhoorelbeke K., Ulrichts H., Schoolmeester A., Staelens S., De Meyer S.
Amplification loops and signal transduction pathways
in "***Thrombosis -Fundamental and Clinical Aspects***" ed. J. Arnout, G. de Gaetano, M. Hoylaerts, K. Peerlinck, C. Van Geet, R. Verhaeghe
Leuven University Press, pp. 75-91, 2003